The vaccine is currently only used in the USA, under an emergency use authorisation.
It was authorised in the EU last month, but the rollout of the vaccine has not started yet in any EU member states.
It is expected to begin in the next few weeks, with Irish Health Minister Stephen Donnelly revealing earlier this week that just over 40,000 of the vaccines are expected to arrive in Ireland this month.
The EMA s statement read: It is currently not clear whether there is a causal association between vaccination with Covid-19 Vaccine Janssen and these conditions.
Janssen Pharmaceutica is a Belgium-based division of Johnson & Johnson.
NIAC to consider findings on AstraZeneca vaccine
Updated / Thursday, 8 Apr 2021
08:14
The AstraZeneca jab makes up a fifth of the four million doses due to be received in Ireland over the next three months
Legal Affairs Correspondent
The National Immunisation Advisory Committee (NIAC) will decide in the coming days if it needs to issue further advice to Government about the AstraZeneca vaccine.
It follows the finding by Europe s medicines regulator that there is a possible link between the vaccine and rare blood clotting in adults.
NIAC has said it will consult with EU colleagues and will consider over the coming days if it needs to issue further advice to the Department of Health in light of the decision by the European Medicines Agency (EMA).
);
A round-up of NPHET’s press briefing at the Department of Health this evening. By Orla Dwyer Thursday 8 Apr 2021, 8:08 PM Thu 8:08 PM 36,982 Views 49 Comments
Professor Philip Nolan at the NPHET briefing this evening.
Image: Sam Boal
Image: Sam Boal
PUBLIC HEALTH OFFICIALS this evening confirmed a further 400 cases of Covid-19 and seven additional deaths in Ireland.
This evening’s figures mean that there has now been a total of 239,723 cases of Covid-19 in Ireland, along with 4,737 deaths.
The deputy Chief Medical Officer Dr Ronan Glynn led tonight’s NPHET briefing, alongside the chair of the NPHET Irish Epidemiological Modelling Advisory Group Professor Philip Nolan, virologist and Director of the National Virus Reference Laboratory Dr Cillian de Gascun and Chief Executive of the Health Products Regulatory
);
);
The European Medicines Agency (EMA) has today concluded a review of cases of unusual blood clots, combined with low blood platelets, which have occurred in people vaccinated with the Covid-19 vaccine Astrazeneca (Vaxzevria®).
The Health Products Regulatory Authority (HPRA) participated in the scientific review of this important safety issue, through participation in the EMAs Pharmacovigilance and Risk Assessment Committee (PRAC).
HPRA is a state agency, which uses its scientific and clinical expertise to review and monitor health products available in Ireland or exported abroad. HPRA s aim is to make sure that health products we regulate are as safe as possible and do what they are intended to do.
Explainer: What is known about the AstraZeneca blood clot reports so far
The National Immunisation Advisory Committee is to decide if further advice needs to be issued about the AstraZeneca vaccine. By Adam Daly Thursday 8 Apr 2021, 2:54 PM 3 hours ago 13,089 Views 15 Comments
Image: Shutterstock/Dimitris Barletis
Image: Shutterstock/Dimitris Barletis
A EUROPEAN MEDICINES Agency (EMA) recommendation yesterday that a specific type of blood clot should be listed as a “very rare side effect” of the AstraZeneca jab stopped just short of saying there is a causal link between the vaccine and the condition.
Questions have been raised over the last number of weeks on whether these highly unusual blood clots among those getting the AstraZeneca vaccine against Covid-19 were more frequent than in the general population, and what